<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>696</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15731234</PubmedId>
            <Abstract>Severe acute respiratory syndrome (SARS) is a recently emerged infectious disease caused by a novel strain of coronavirus. Examination of the immune responses of patients who have recovered from SARS should provide important information for design of a safe and effective vaccine. We determined the continuous viral epitopes targeted by antibodies in plasma samples from convalescent SARS patients through biopanning with a vast M13 phage display dodecapeptide library. These epitopes converged to very short peptide fragments, one on each of the structural proteins spike and nucleocapsid and the nonstructural proteins 3a, 9b, and nsp 3. Immunoassays found that most of the patients who had recovered from SARS developed complementary antibodies to the epitope-rich region on the spike S2 protein, indicating that this is an immunodominant site on the viral envelope comprising the spike, matrix, and small envelope glycoproteins. These S2-targeting antibodies were shown to effectively neutralize the coronavirus, indicating that they provided protective immunity to help the patients recover from the viral infection. These results suggest that the SARS coronavirus might have an antigenic profile distinct from those of other human or animal coronaviruses. Due to the tested safety and protective effects of the convalescent-phase serological antibodies, identification of their complementary antigens may enable the design of an epitope-based vaccine to prevent potential antibody-mediated immunopathology.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>3401-8</ArticlePages>
            <ArticleTitle>B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Zhong</LastName>
                    <ForeName>Xiaofen</ForeName>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Huanghao</ForeName>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Zu-Feng</ForeName>
                </Author>
                <Author>
                    <LastName>Sin</LastName>
                    <ForeName>Wan-Yee Fion</ForeName>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Wei</ForeName>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Junjie</ForeName>
                </Author>
                <Author>
                    <LastName>Fu</LastName>
                    <ForeName>Ling</ForeName>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Jie</ForeName>
                </Author>
                <Author>
                    <LastName>Mak</LastName>
                    <ForeName>Chun-Kit Gannon</ForeName>
                </Author>
                <Author>
                    <LastName>Cheng</LastName>
                    <ForeName>Chak-Sum Samuel</ForeName>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Yanzhen</ForeName>
                </Author>
                <Author>
                    <LastName>Cao</LastName>
                    <ForeName>Shuyong</ForeName>
                </Author>
                <Author>
                    <LastName>Wong</LastName>
                    <ForeName>Tin-Yau</ForeName>
                </Author>
                <Author>
                    <LastName>Lai</LastName>
                    <ForeName>Sik-To</ForeName>
                </Author>
                <Author>
                    <LastName>Xie</LastName>
                    <ForeName>Yong</ForeName>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Zhihong</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.</Affiliations>
            <ArticleChemicalList>3a protein, severe acute respiratory syndrome coronavirus;Antibodies, Viral;Antigens, Viral;Immunodominant Epitopes;Membrane Glycoproteins;Nucleocapsid Proteins;Peptide Library;Spike Glycoprotein, Coronavirus;Viral Envelope Proteins;Viral Nonstructural Proteins;Viral Proteins;nonstructural protein, coronavirus;nucleocapsid protein, Coronavirus;spike glycoprotein, SARS-CoV</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adult; Aged; Antibodies, Viral(blood); Antigens, Viral(immunology); B-Lymphocytes(immunology); Epitope Mapping; Hong Kong; Humans; Immunodominant Epitopes; Membrane Glycoproteins(immunology); Middle Aged; Neutralization Tests; Nucleocapsid Proteins(immunology); Peptide Library; SARS Virus(immunology); Severe Acute Respiratory Syndrome(immunology); Spike Glycoprotein, Coronavirus; Viral Envelope Proteins(immunology); Viral Nonstructural Proteins; Viral Proteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>79</Volume>
                <Issue>6</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>SL26 Epitope-rich fragment</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QILPDPLKPTKRSFIEDLLFNKVTLA</LinearSequence>
                        <ModifiedResidues>Q1</ModifiedResidues>
                        <Modifications>Acetylation|ACET</Modifications>
                        <StartingPosition>786</StartingPosition>
                        <EndingPosition>811</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P59594.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>694009</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 2</LocationOfData>
                <EpitopeId>51097</EpitopeId>
                <ReferenceStartingPosition>786</ReferenceStartingPosition>
                <ReferenceEndingPosition>811</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>This sequence is denoted by authors as an epitope-rich region encompassing an identified convergent region for antibody from convlescent sera of SARS-CoV patients who have recovered.   The authors identified 5 peptides within this region and these peptidesfell into two distinct groups of peptides corresponding to two putatively distinct distinct epitopes.  For experimental purposes the N-terminus of the synthetic peptide was N-acetylated.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>6971</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>40</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>23</NumberOfSubjectsResponded>
                            <ResponseFrequency>57.5</ResponseFrequency>
                            <AssayComments>This immunoblot contained S2 protein (aa 681-1203) bound to membrane.  Sera was pre-adsorbed with SL26 prior to addtion to the membrane.  S2-targeting Abs were detected in 33 out of the 40 samples (control experiment using SARS-CoV virus bound to membrane).  Of those, 23 were signficantly blocked by SL26 epitopic region peptide.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>anti-spike S2 Ab (from convalescent plasma)</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>SL26 Epitope-rich fragment</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QILPDPLKPTKRSFIEDLLFNKVTLA</LinearSequence>
                                        <ModifiedResidues>Q1</ModifiedResidues>
                                        <Modifications>Acetylation|ACET</Modifications>
                                        <StartingPosition>786</StartingPosition>
                                        <EndingPosition>811</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>6972</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Protection of SARS-CoV infection of Vero E6 cells was measured by addition of sera from convalescent patient J.  Blocking of protection was demonstrated by pre-mixing sera with SL21 epitopic region.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>anti-spike S2 Ab (from convalescent plasma)</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>SL26 Epitope-rich fragment</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QILPDPLKPTKRSFIEDLLFNKVTLA</LinearSequence>
                                        <ModifiedResidues>Q1</ModifiedResidues>
                                        <Modifications>Acetylation|ACET</Modifications>
                                        <StartingPosition>786</StartingPosition>
                                        <EndingPosition>811</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

